ImmuneXcite Receives $5,761,038 New Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    3 Forbes Road Lexington, MA 02421 USA
  • Company Description
    ImmuneXcite has developed a proprietary platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for oncological and infectious disease targets.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. Total Amount Sold includes conversion of outstanding convertible promissory notes. SEC regulatory filing. Amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt.
  • M&A Terms
  • Venture Investor

Trending on Xconomy